Yükleniyor... / Loading...
This study looks at how children with atopic dermatitis (eczema) respond to a medication called Crisaborole (Eucrisa). Children with mild to moderate atopic dermatitis affecting at least 5% of their body surface could take part. It was conducted in Phase 4 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * AD diagnosis by dermatologist or allergist based on Hanifin and Rajka criteria * 5% or more treatable body surface area involvement * baseline Investigator's Static Assessment (ISGA) score of mild (2) or moderate (3) * patient on stable regimens (consistent use 14 days before day 1 of enrollment) of inhaled corticosteroids and antihistamines * must have lesional skin in the antecubital fossa Exclusion Criteria: * use of topical corticosteroid, calcineurin inhibitor, or PDE4 inhibitor within 14 days of enrollment * significant active infection * any previous use of biologic therapy * no pruritus at baseline visit, or other pruritic condition * washing/moisturizer use 24 hours prior to tape strip biomarker collection at site * uncontrolled asthma, uncontrolled allergic rhinitis, or other sleep disturbing condition